RT Journal Article SR Electronic T1 Syndromic surveillance insights from a symptom assessment app before and during COVID-19 measures in Germany and the United Kingdom: results from repeated cross-sectional analyses JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.16.20126466 DO 10.1101/2020.06.16.20126466 A1 Alicia Mehl A1 Francois Bergey A1 Caoimhe Cawley A1 Andreas Gilsdorf YR 2020 UL http://medrxiv.org/content/early/2020/06/19/2020.06.16.20126466.abstract AB Background Unprecedented lockdown measures have been introduced in countries across the world to mitigate the spread and consequences of COVID-19. While attention has focused on the effects of these measures on epidemiological indicators relating directly to the infection, there is increased recognition of their broader health implications. However, assessing these implications in real time is a challenge, due to limitations of existing syndromic surveillance data and tools.Objective To explore the added value of mobile phone app-based symptom assessment tools as real time health insight providers to inform public health policy makers.Methods A comparative and descriptive analysis of the proportion of all self-reported symptoms entered by users during an Ada assessment in Germany and the United Kingdom (UK) was conducted between two periods: before and after the implementation of “Phase One” COVID-19 measures. Additional analyses were performed to explore the association between symptom trends and seasonality, and symptom trends and weather. Differences in the proportion of unique symptoms between the periods were analysed using Pearson’s Chi-squared test and reported as Log2 Fold Changes (Log2 FC).Results Between 48,300-54,900 symptomatic users reported 140,500-170,400 symptoms during the Baseline and Measures periods in Germany. Between 34,200-37,400 symptomatic users in the UK reported 112,100-131,900 symptoms during the Baseline and Measures periods. The majority of symptomatic users were female (Germany 68,600/103,200, 66.52%; UK 51,200/71,600, 72.74%). The majority (Germany 68,500/100,000, 68.45%; UK 50,900/68,800, 73.91%) were aged between 10 and 29 years, and about a quarter (Germany 26,200/100,000, 26.15%; UK 14,900/68,800, 21.65%) were between 30-59 years. 103 symptoms were reported either more or less frequently (with statistically significant differences) during the Measures as compared to the Baseline period, and 34 of these were found in both countries. The following mental health symptoms (Log2 FC, P-value) were reported less often during the Measures period: inability to manage constant stress and demands at work (−1.07, P<.001), memory difficulty (−0.56, P<.001), depressed mood (−0.42, P<.001), and impaired concentration (−0.46, P<.001). Diminished sense of taste (2.26, P<.001) and hyposmia (2.20, P<.001) were reported more frequently during the Measures period. None of the 34 symptoms were found to be different between the same dates in 2019. Fourteen of the 34 symptoms had statistically significant associations with weather variables.Conclusions Symptom assessment apps have an important role to play in facilitating improved understanding of the implications of public health policies such as COVID-19 lockdown measures. Not only do they provide the means to complement and cross-validate hypotheses based on data collected through more traditional channels, they can also generate novel insights through a real-time syndromic surveillance system.Competing Interest StatementThe authors are employees of Ada Health GmbH.Funding StatementThis study was funded by Ada Health GmbH. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Clinical Governance Board of Ada Health has approved the ethical oversight of our study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhen possible, data relevant to the study are included in the article or uploaded as supplementary information.°Cdegrees CelsiusCOVID-19Coronavirus disease 2019GDPRGeneral Data Protection RegulationICD-10International Classification of Diseases version 2019Log2 FLog2 Fold ChangemmmillimetersP-valueprobability valueUKUnited Kingdom